Despite billions in R&D, oncology target selection remains remarkably qualitative. At Bio-IT World 2026, our CEO Andreas Stuhlmüller shared how we're thinking about this problem.
The idea: Turn the target review into a living causal model. The model maps out what has to be true
Elicit
1,684 posts
- Elicit repostedWe built a reasoning native programming language because LLMs break at scale🧠NEW EPISODE: @stuhlmueller and @jungofthewon , co-founders of @elicitorg , are back on The Cognitive Revolution with @labenz after two years — and the mission hasn't moved an inch: radically improve the quality of reasoning behind high-stakes decisions. What's changed is how
00:00 - Elicit reposted🧠NEW EPISODE: @stuhlmueller and @jungofthewon , co-founders of @elicitorg , are back on The Cognitive Revolution with @labenz after two years — and the mission hasn't moved an inch: radically improve the quality of reasoning behind high-stakes decisions. What's changed is how
00:00 - A fair question about any data extraction tool: can you actually trust what it pulls? Farhad Shokraneh, PhD, an SLR methodologist at Systematic Review Consultants ran a scoping review for a policy brief and used Elicit to check the accuracy of each data point. Below he shares his
- The recording from yesterday's webinar is live: What's Next in AI for Life Sciences: Evaluating Superhuman AI. AI is outpacing the evaluation playbook. Accuracy, precision, and recall work for simple tasks, but break down once AI takes on evidence synthesis, multi-stepElicit co-founder and COO Jungwon Byun breaks down how to evaluate AI for evidence and research with more rigor: - Where old evaluation methods fail - A practical framework for evaluating superhuman AI - How to catch confirmation bias and sycophancy in AI-written reports - How
- Elicit repostedThe more I think about it, the more bullish I am on @elicitorg in a world of very good models. We're going to do so much good reasoning
- Monday's webinar is officially at capacity. The response to "What's Next in AI for Life Sciences: Evaluating Superhuman AI" has been incredible. Thank you to everyone who registered. If you didn't get a spot, we've got you covered. Fill out the form below to receive the
- We're heading to DIA from June 14-18 in Philly. DIA brings together key stakeholders in life sciences across regulatory, clinical, safety, medical affairs, quality, and policy. We want to meet as many of you as we can and hear how AI is actually changing the day-to-day of your
- Can Elicit's full-text screening recall every relevant paper in a systematic review? We evaluated Elicit's recall using 74 Cochrane reviews and 377 studies. The results: 99.5% Paper-level recall 94.8% Per-criterion accuracy For teams running systematic reviews, this means
- As AI scales from basic tasks to complex automation, the ability to rigorously evaluate these tools is becoming the ultimate competitive advantage for life sciences teams. When AI starts drafting strategy documents or navigating autonomous goals, traditional metrics like
- We asked Elicit this question and got three answers 1. ITER's first plasma 2. Space – Artemis and SpaceX's missions have had their timelines pushed back 3. Solid state batteries. Toyota has pushed it's estimate of solid state EV batteries by about three yearsCan anyone think of a technology domain where the timelines for progress have gotten longer over the last 4 years? (Don’t look at other replies before thinking about it)
- GLP-1 receptor agonists like Ozempic have surprising effects! There is growing evidence that they 1. Reduce suicidal intentions 2. Reduce dementia 3. Reduce heavy drinking days for people suffering from alcoholism
- Elicit repostedTo what extent do scientists overall peak in their 20s? We asked Elicit this question and it gave us a really interesting answer - mostly not! - Most fields have it after their 20s - The mean Nobel winning age has gone up by about a decade - Experimental Nobel-winning
















